Company Valuation: RAPT Therapeutics, Inc.

Data adjusted to current consolidation scope
Fiscal Period: December 2020 2021 2022 2023 2024 2025 2026 2027
Market Cap 1 485 1,085 672 854.7 213.2 1,794 1,794 -
Change - 123.77% -38.08% 27.19% -75.05% 741.39% 0% -
Enterprise Value (EV) 373.5 895.6 422.9 695.9 -17.82 1,794 1,794 1,794
Change - 139.81% -52.77% 64.53% -102.56% 10,167.55% 0% 0%
P/E -9.02x -14.5x -7.67x -8.15x -0.5x - - -
PBR 4.7x 5.82x 2.77x 5.81x 0.39x - - -
PEG - -0.9x -3.88x -0.4x -0.11x - - -
Capitalization / Revenue 96.2x 285x 440x - - - - -
EV / Revenue 0x 0x 0x - - - - -
EV / EBITDA - - - - - - - -
EV / EBIT - - - - - - -18,104,290x -12,616,984x
EV / FCF - - - - - - - -
FCF Yield - - - - - - - -
Dividend per Share 2 - - - - - - - -
Rate of return - - - - - - - -
EPS 2 -17.52 -20.24 -20.64 -24.4 -25.52 - - -
Distribution rate - - - - - - - -
Net sales 1 5.042 3.813 1.527 - - - - -
EBITDA -52.09 -68.21 -84.75 -125.8 -134.9 - - -
EBIT -53.21 -69.21 -85.8 -127.1 -136.1 - -99.1 -142.2
Net income -52.89 -69.2 -83.84 -116.8 -129.9 - - -
Net Debt -111.5 -189.7 -249.1 -158.9 -231.1 - - -
Reference price 2 158.00 293.84 158.40 198.80 12.64 58.02 58.02 58.02
Nbr of stocks (in thousands) 3,069 3,693 4,243 4,300 16,870 30,923 30,923 -
Announcement Date 3/11/21 3/10/22 3/14/23 3/7/24 3/6/25 - - -
1USD in Million2
Estimates


P/E (Y) EV / Sales (Y) EV / EBITDA (Y) Dividend Yield (Y) Capi.($)
- - - - 1.79B
20.25x7.04x14.2x1.45% 67.98B
36.9x9.64x29.44x0.04% 64.94B
-77.3x14.92x-71.95x-.--% 27.58B
-15.85x6.12x-7.7x-.--% 26.06B
29.69x6.35x16.48x-.--% 25.74B
27.41x5.13x17.06x-.--% 20.09B
49.41x18.23x36.98x0.31% 17.16B
1289.22x37.23x812.54x-.--% 14.92B
18.23x5.44x12.69x-.--% 14.62B
Average 153.11x 12.23x 95.53x 0.2% 28.09B
Weighted average by Cap. 82.01x 10.35x 51.60x 0.38%

Y-o-Y evolution of P/E

Historical PBR trend

Evolution Enterprise Value / Sales

Change in Enterprise Value/EBITDA


  1. Stock Market
  2. Stocks
  3. RAPT Stock
  4. Valuation RAPT Therapeutics, Inc.